Nyrada Inc (ASX: NYR) Share Price and News

Dr Dixon brings to the Board entrepreneurial and technical experience in founding, building, and running listed and unlisted technology-based companies. In 2014, he co-founded Cardio Therapeutics Pty Ltd and managed the PCSK9 cardiovascular discovery program until the company was acquired by Nyrada Inc in advance of the IPO of Nyrada in 2019. He is member of Risk Committee.

Mr Moore has leadership experience across multiple industries. He currently serves on the boards of two private and three public companies. In the life sciences sector, he is Chairman of Scientific Industries (SCND-OTCQB), a manufacturer of laboratory instruments, and Trialogics, a clinical trial informatics company. He also serves as a director of Phase Holographic Imaging, a provider of live cell imaging systems for life science researchers. Phase Holographic is publicly traded on both the Swedish Spotlight Market and the OTCQB in the U.S. He is also a member of Risk Committee.

Mr Bonnar has over 20 years of experience in the global Life Sciences industry, including pre-clinical research, operations management, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, and Quality Assurance. Before joining Nyrada, James was at Neuren for eleven years. During this period, he was the Director, CMC and Regulatory Affairs and then Director, Clinical Operations where he oversaw clinical development for drugs in the areas of traumatic brain injury and neuro-developmental disorders. Prior to that, he worked in diabetes research, GMP manufacturing, and drug formulation development. James brings an experienced scientific focus to Nyrada, having led teams from early stage development through to end of Phase II.

Mr Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 19 years he has led more than 80 transactions for the health care division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, he spent five years as a Biotech/Pharma Equity Analyst, at Gontard and Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as three years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen.

Mr Cox is a Co-Founder and a General Partner of Population Health Partners, L.P., a global healthcare focused investment firm since April 2020. He serves on the boards of Scientific Industries (SCND-OTXQB), a manufacturer of laboratory instruments; Niroda Therapeutics, a private biopharmaceutical company focused on the development and commercialization of non-opioid therapeutics for acute and chronic pain; and Civia Health, a private clinical trial site management organization. Previously, from January 2012, he was a partner, Chairman of the Corporate Department, and a member of the management committee of Cadwalader, Wickersham and Taft LLP, a global law firm.

Mr Frampton manages the investment team at APFC and leads all investment decisions related to APFC's investment portfolio within the guidelines established by APFC's Board of Trustees. Before joining the APFC in 2012, he held positions ranging from Investment Banking Analyst and Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005- 2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012). He is Chair of Risk Committee.

-

-